Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Ok here is a PR that is "PAR" for PTSC.. PDGS will not hit the 3-6 million ..

Re: We will see if you are right but what do you think is "likely a substantial one"(loss)

The list of expenses (including line items that can be moved from capital to expense) that could be accrued into current Q results might be very large indeed. Some examples are start-up expenses, program development costs, and lay-off plans, multi Q consulting fees.

This is total speculation on my part, but given managements past moves I'd say this could be a bigger loss Q then we've seen in the past several years. This does not suggest manipulation and is not necessarily bad in the longer run.

Cautious

Share
New Message
Please login to post a reply